Bladder Cancer

>

Latest News

High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro
High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro

June 5th 2024

A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.

Enfortumab Vedotin With Pembro Improves Survival, Maintains QOL in Urothelial Cancer
Enfortumab Vedotin With Pembro Improves Survival, Maintains QOL in Urothelial Cancer

June 3rd 2024

Data Update: 2-Year EFS Is Achieved With Neoadjuvant Enfortumab Vedotin in MIBC
Data Update: 2-Year EFS Is Achieved With Neoadjuvant Enfortumab Vedotin in MIBC

June 2nd 2024

Real-World Sacituzumab Govitecan Yields Lower ORR Post-EV in mUC
Real-World Sacituzumab Govitecan Yields Lower ORR Post-EV in mUC

June 2nd 2024

Cisplatin in Combination with Avelumab Shows Promising Survival in MIUC
Cisplatin in Combination with Avelumab Shows Promising Survival in MIUC

June 1st 2024

Video Series
Video Interviews

More News